HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?

Seo, Mikyung Kelly; Straume, Oddbjørn; Akslen, Lars A; Cairns, John

Seo, Mikyung Kelly; Straume, Oddbjørn; Akslen, Lars A; Cairns, John.

Afiliación

Seo MK; Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. seokelly@gmail.com.
Straume O; Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway. seokelly@gmail.com.
Akslen LA; Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway.
Cairns J; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.

Pharmacoecon Open ; 4(3): 529-539, 2020 Sep.

Article en En | MEDLINE | ID: mdl-31989465

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Pharmacoecon Open Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google